Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

7 results
Display

The impact of sarcopenia on the results of lumbar spinal surgery

Inose H, Yamada T, Hirai T, Yoshii T, Abe Y, Okawa A

  • Osteoporos Sarcopenia.
  • 2018 Mar;4(1):33-36.
  • doi: 10.1016/j.afos.2018.02.003
OBJECTIVES: As the population ages, the number of lumbar spinal surgeries performed on sarcopenic patients will increase. The purpose of this study was to investigate the prevalence of sarcopenia and...
Utility of radius bone densitometry for the treatment of osteoporosis with once-weekly teriparatide therapy

Nakayama H, Toho H, Sone T

  • Osteoporos Sarcopenia.
  • 2018 Mar;4(1):29-32.
  • doi: 10.1016/j.afos.2018.02.001
OBJECTIVES: As clinics that treat patients with osteoporosis do not usually have central dual-energy X-ray absorptiometry (DXA), bone density is often measured with radial DXA. However, no long-term evidence exists...
Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis

Takeuchi Y, Hashimoto , Nishida Y, Yamagiwa C, Tamura T, Atsumi A

  • Osteoporos Sarcopenia.
  • 2018 Mar;4(1):22-28.
  • doi: 10.1016/j.afos.2018.01.001
OBJECTIVES: This postmarketing, observational study evaluated the safety and effectiveness of monthly intravenous (IV) ibandronate in Japanese patients with osteoporosis. METHODS: Eligible patients received monthly IV ibandronate 1mg for 12 months....
An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study

Cheung CL, Ang SB, Chadha M, Chow ES, Chung YS, Hew FL, Jaisamrarn U, Ng H, Takeuchi Y, Wu CH, Xia W, Yu J, Fujiwara S

  • Osteoporos Sarcopenia.
  • 2018 Mar;4(1):16-21.
  • doi: 10.1016/j.afos.2018.03.003
OBJECTIVES: Hip fracture is a major public health problem. Earlier studies projected that the total number of hip fracture will increase dramatically by 2050, and most of the hip fracture...
Romosozumab for the treatment of osteoporosis

McClung MR

  • Osteoporos Sarcopenia.
  • 2018 Mar;4(1):11-15.
  • doi: 10.1016/j.afos.2018.03.002
Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of...
Individualized fracture risk assessment: State-of-the-art and room for improvement

Nguyen TV

  • Osteoporos Sarcopenia.
  • 2018 Mar;4(1):2-10.
  • doi: 10.1016/j.afos.2018.03.001
Fragility fracture is a serious clinical event, because it is associated with increased risk of mortality and reduced quality of life. The risk of fracture is determined by multiple risk...
Factors associated with osteoporosis medication initiation and adherence

Rhee Y

  • Osteoporos Sarcopenia.
  • 2018 Mar;4(1):1-1.
  • doi: 10.1016/j.afos.2018.02.002
No abstract available.

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr